ArticleJournal of cancer research and clinical oncology2021
Coexistence of regression and tumor infiltrating lymphocytes is associated with more favorable survival in melanoma.
Article in Journal of cancer research and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
- Advances in Tumor-Infiltrating Lymphocyte (TIL) as a Prognostic Factor and for Treating Invasive Cutaneous Melanoma.International journal of molecular sciences · 2024Review
- Role of tumor-infiltrating lymphocytes in melanoma prognosis and treatment strategies: A systematic review and meta-analysis.Heliyon · 2024Article
- Tumor-infiltrating lymphocytes as a prognostic and predictive factor for Melanoma.Expert review of molecular diagnostics · 2024Review
- Addressing the importance of melanoma tumor-infiltrating lymphocytes in disease progression and clinicopathological characteristics.Molecular and clinical oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMelanoma is one of the highly immunogenic malignancies, and histological regression (HR) and tumor infiltrating lymphocytes (TILs) represent early signs of activation of the immune system against primary melanoma. In this study we aimed to investigate the potential roles of HR and TILs on survival, as combined or separately.
methodsA total of 916 cutaneous melanomas were analyzed retrospectively.
resultsOnly minority of the lesions had HR (25.1%) and they were associated with males (p = 0.002), axial localization (p = 0.0001), non-nodular histopathology (p = 0.0001), thin Breslow depth (p = 0.01) and nevus-associated melanoma (p = 0.03). Those with TILs (48.4%) were found in association with lower Clark levels (p = 0.003), thin tumor thicknesses (p = 0.001), lower mitotic rates (p = 0.02), BRAF mutation (p = 0.03), absence of neurotropism (p = 0.03), involvement of lymph node (p = 0.0001) and relapse of disease (p = 0.04). A significant relationship was found between HR and TILs (p = 0.01). TILs were independently associated with favorable RFS (p = 0.02), whereas no relationship was observed between HR and RFS (p = 0.2). A marked favorable survival advantage was noted in the group with HR (+)/TILs (+) compared to other groups with HR (-)/TILs (-) (p = 0.007), only HR (+) and only TILs (+). Both HR (p = 0.05) and TILs (p = 0.04) were correlated with favorable OS rates. Moreover, HR (+) /TILs (+) patients had more favorable OS than other groups with HR (-)/TILs (-) (p = 0.002), only HR (+) and only TILs (+).
conclusionOnly HR (+) and only TILs (+) subgroups separately were found to be associated with favorable survivals in melanoma. Furthermore, coexistence of HR and TILs, HR (+)/TILs (+) subgroup, had more favorable survival rates compared to only HR (+) and only TILs (+) subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.